查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1842107

全球HPV相關疾病市場：市場規模、佔有率和趨勢分析（按類型、治療方法、分銷管道和地區分類），細分市場預測（2025-2033年）

HPV Associated Disorders Market Size, Share & Trends Analysis Report By Type, (Cervical Intraepithelial Neoplasia (CIN), Cervical Cancer), By Treatment (Vaccines, Anti-viral Drugs), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

HPV相關疾病：市場概覽

全球 HPV 相關疾病市場預計在 2024 年達到 185 億美元，預計到 2033 年將達到 285 億美元，2025 年至 2033 年的複合年成長率為 4.9%。

由於全球HPV感染病例的不斷增加，該產業正經歷強勁成長。

持續性HPV感染被認為是子宮頸癌、肛門癌、外陰癌、陰道癌、陰莖癌和口咽癌的主要原因之一，因此需要及時診斷和治療。能夠準確檢測高風險HPV病毒株的分子診斷檢測需求日益成長，推動了其在臨床中的應用，同時醫療系統也優先開展篩檢項目，以早期發現癌前病變。例如，根據世界衛生組織（WHO）2024年3月的一項研究，人類乳突病毒（HPV）包含約200種已知病毒類型。雖然大多數感染是無害的，但某些高危險型HPV會引起生殖器濕疣和各種癌症。約90%的病例中，人體可自然清除感染。據估計，2019年HPV導致約62萬例女性癌症和7萬例男性癌症。到2022年，子宮頸癌將成為女性第四大癌症死因，全球整體新增病例達66萬例，死亡人數達35萬人。子宮頸癌佔女性所有HPV相關癌症的90%以上。這些數據凸顯了HPV相關疾病在全球範圍內造成的巨大負擔，並推動了對先進診斷技術和有效治療的需求。

治療方案的進步是HPV相關疾病市場的另一個大成長動力。包括免疫療法和標靶藥物在內的創新治療方法正日益受到關注，因為它們能夠改善HPV誘發惡性腫瘤患者的預後。製藥公司正大力投資研發，以期將新型治療方法推向市場並強化其治療產品線。例如，2025年4月，BioMed Central Ltd.的研究人員報告稱，人類乳突病毒（HPV）這種DNA病毒已被證實是子宮頸癌、外陰癌、陰道癌、陰莖癌、肛門癌以及頭頸癌的致病因素。他們指出，持續感染以及某些HPV基因型的致癌性是大多數HPV相關癌症的驅動因子。

目錄

第1章 分析方法和範圍

第2章執行摘要

第3章：HPV相關疾病市場：促進因素、趨勢與範圍

  • 市場聯動展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析：波特五力分析
    • PESTEL 分析
    • 管道分析
    • 專利到期分析
    • 定價分析

第4章 HPV相關疾病市場：按類型分類的業務分析

  • 按類型分類的市場佔有率（2024 年和 2033 年）
  • 按類型分類的儀表板
  • 按類型分類的市場規模預測和趨勢分析（2021-2033）
  • 子宮頸上皮內瘤（CIN）
  • 子宮頸癌
  • 肛門上皮內瘤（AIN）
  • 肛門癌
  • 生殖器疣
  • 其他

第5章 HPV相關疾病市場：依治療方法的業務分析

  • 按治療方法的市場佔有率（2024 年和 2033 年）
  • 治療方法專用儀表板
  • 按治療方法的市場規模預測和趨勢分析（2021-2033 年）
  • 疫苗
  • 抗病毒藥物
  • 其他

第6章：HPV相關疾病市場：按分銷管道分類的業務分析

  • 按分銷管道分類的市場佔有率（2024 年和 2033 年）
  • 分銷通路儀錶板
  • 按分銷管道分類的市場規模預測和趨勢分析（2021-2033）
  • 醫院藥房
  • 零售藥房
  • 其他

第7章 HPV相關疾病市場：區域估算與趨勢分析

  • 按地區分類的市場佔有率分析（2024 年和 2033 年）
  • 市場概覽：按地區
  • 市場規模預測及趨勢分析（2021-2033）
  • 北美洲
    • 按國家/地區分類（2021-2033 年）
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭情勢

  • 參與企業概況
  • 企業市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介/上市公司
    • Merck &Co., Inc.
    • GlaxoSmithKline plc
    • F. Hoffmann-La Roche Ltd
    • Pfizer Inc.
    • AstraZeneca
    • Biocon
    • Lilly
    • AbbVie Inc.
Product Code: GVR-3-68038-436-9

HPV Associated Disorders Market Summary

The global HPV associated disorders market size was estimated at USD 18.5 billion in 2024 and is projected to reach USD 28.5 billion by 2033, growing at a CAGR of 4.9% from 2025 to 2033. The industry is witnessing strong growth due to the rising prevalence of HPV infections worldwide.

Persistent HPV infections are recognized as a major cause of cervical, anal, vulvar, vaginal, penile, and oropharyngeal cancers, which has increased the need for timely diagnosis and treatment. Growing demand for molecular diagnostic tests that can accurately detect high-risk HPV strains is fueling adoption in clinical settings, while healthcare systems are prioritizing screening programs to identify precancerous changes early. For instance, in March 2024, World Health Organization findings indicated that human papillomavirus (HPV) encompassed a group of around 200 known viruses, with most infections remaining harmless while some high-risk types caused genital warts and various cancers. In approximately 90% of cases, the body naturally cleared the infection. In 2019, HPV was estimated to have caused about 620,000 cancer cases in women and 70,000 in men. Cervical cancer became the fourth leading cause of cancer among women in 2022, with 660,000 new cases and 350,000 deaths globally. Cervical cancers represented over 90% of all HPV-related cancers in women. These figures highlight the substantial global burden of HPV-related disease, strengthening the demand for advanced diagnostics and effective treatments.

Advancements in treatment solutions represent another major growth driver for the HPV associated disorders market. Innovative therapies, including immunotherapies and targeted drugs, are gaining traction as they provide improved outcomes for patients with HPV-driven malignancies. Pharmaceutical companies are investing heavily in research and development to bring novel therapies into the landscape, strengthening the treatment pipeline. For instance, in April 2025, authors at BioMed Central Ltd. reported that human papillomavirus (HPV), a DNA virus, had been established as a causative agent of cervical, vulvar, vaginal, penile, anal, and head & neck cancers. They noted that persistent infection and the oncogenic potential of certain HPV genotypes drove most HPV-related cancers.

Global HPV Associated Disorders Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global HPV associated disorders market report based on type, treatment, distribution channel, and region:

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Cervical Intraepithelial Neoplasia (CIN)
  • Cervical Cancer
  • Anal Intraepithelial Neoplasia (AIN)
  • Anal Cancer
  • Genital Warts
  • Others
  • Treatment Outlook (Revenue, USD Million, 2021 - 2033)
  • Vaccines
  • Anti-viral Drugs
  • Others
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Treatment
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. HPV Associated Disorders Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. HPV Associated Disorders Market: Type Business Analysis

  • 4.1. Type Market Share, 2024 & 2033
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
  • 4.4. Cervical Intraepithelial Neoplasia (CIN)
    • 4.4.1. Cervical Intraepithelial Neoplasia (CIN) Market, 2021 - 2033 (USD Million)
  • 4.5. Cervical Cancer
    • 4.5.1. Cervical Cancer Market, 2021 - 2033 (USD Million)
  • 4.6. Anal Intraepithelial Neoplasia (AIN)
    • 4.6.1. Anal Intraepithelial Neoplasia (AIN) Market, 2021 - 2033 (USD Million)
  • 4.7. Anal Cancer
    • 4.7.1. Anal Cancer Market, 2021 - 2033 (USD Million)
  • 4.8. Genital Warts
    • 4.8.1. Genital Warts Market, 2021 - 2033 (USD Million)
  • 4.9. Others
    • 4.9.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. HPV Associated Disorders Market: Treatment Business Analysis

  • 5.1. Treatment Market Share, 2024 & 2033
  • 5.2. Treatment Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2021 to 2033 (USD Million)
  • 5.4. Vaccines
    • 5.4.1. Vaccines Market, 2021 - 2033 (USD Million)
  • 5.5. Anti-viral Drugs
    • 5.5.1. Anti-viral Drugs Market, 2021 - 2033 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. HPV Associated Disorders Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2024 & 2033
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution channel, 2021 to 2033 (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. HPV Associated Disorders Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 7.4. North America
    • 7.4.1. North America HPV Associated Disorders Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Target Disease Prevalence
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Framework
      • 7.4.2.5. U.S. HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Target Disease Prevalence
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Framework
      • 7.4.3.5. U.S. HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Target Disease Prevalence
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Framework
      • 7.4.4.5. Mexico HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Target Disease Prevalence
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Framework
      • 7.5.2.5. Uk HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Target Disease Prevalence
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Framework
      • 7.5.3.5. Germany HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Target Disease Prevalence
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Framework
      • 7.5.4.5. France HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Target Disease Prevalence
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Reimbursement Framework
      • 7.5.5.5. Italy HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Target Disease Prevalence
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Reimbursement Framework
      • 7.5.6.5. Spain HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Target Disease Prevalence
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Reimbursement Framework
      • 7.5.7.5. Denmark HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Target Disease Prevalence
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Reimbursement Framework
      • 7.5.8.5. Sweden HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Target Disease Prevalence
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Reimbursement Framework
      • 7.5.9.5. Norway HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Target Disease Prevalence
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Framework
      • 7.6.2.5. Japan HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Target Disease Prevalence
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Framework
      • 7.6.3.5. China HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Target Disease Prevalence
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Framework
      • 7.6.4.5. India HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Target Disease Prevalence
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Framework
      • 7.6.5.5. Australia HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Target Disease Prevalence
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Reimbursement Framework
      • 7.6.6.5. South Korea HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Target Disease Prevalence
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Reimbursement Framework
      • 7.6.7.5. Thailand HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Target Disease Prevalence
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Reimbursement Framework
      • 7.7.2.5. Japan HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Target Disease Prevalence
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Reimbursement Framework
      • 7.7.3.5. China HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Target Disease Prevalence
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Reimbursement Framework
      • 7.8.2.5. South Africa HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Target Disease Prevalence
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Reimbursement Framework
      • 7.8.3.5. Saudi Arabia HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Target Disease Prevalence
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Reimbursement Framework
      • 7.8.4.5. UAE HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Target Disease Prevalence
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Reimbursement Framework
      • 7.8.5.5. Kuwait HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Merck & Co., Inc.
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. GlaxoSmithKline plc
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. F. Hoffmann-La Roche Ltd
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Pfizer Inc.
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. AstraZeneca
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Biocon
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Lilly
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. AbbVie Inc.
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global HPV associated disorders market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 5 Global HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 6 Global HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 7 North America HPV associated disorders market, by country, 2021 - 2033 (USD Million)
  • Table 8 North America HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 9 North America HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 10 North America HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 11 U.S. HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 12 U.S. HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 13 U.S. HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 14 Canada HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 15 Canada HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 16 Canada HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 17 Mexico HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 18 Mexico HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 19 Mexico HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 20 Europe HPV associated disorders market, by country, 2021 - 2033 (USD Million)
  • Table 21 Europe HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 22 Europe HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 23 Europe HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 24 UK HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 25 UK HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 26 UK HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 27 Germany HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 28 Germany HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 29 Germany HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 30 France HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 31 France HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 32 France HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 33 Italy HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 34 Italy HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 35 Italy HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 36 Spain HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 37 Spain HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 38 Spain HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 39 Norway HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 40 Norway HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 41 Norway HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 42 Denmark HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 43 Denmark HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 44 Denmark HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 45 Sweden HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 46 Sweden HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 47 Sweden HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific HPV associated disorders market, by country, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific HPV associated disorders market, by type, 2021 - 2033 (USD
  • Table 50 Asia Pacific HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 52 Japan HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 53 Japan HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 54 Japan HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 55 China HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 56 China HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 57 China HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 58 India HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 59 India HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 60 India HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 61 Australia HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 62 Australia HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 63 Australia HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 64 South Korea HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 65 South Korea HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 66 South Korea HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 67 Thailand HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 68 Thailand HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 69 Thailand HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 70 Latin America HPV associated disorders market, by country, 2021 - 2033 (USD Million)
  • Table 71 Latin America HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 72 Latin America HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 73 Latin America HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 74 Brazil HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 75 Brazil HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 76 Brazil HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 77 Argentina HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 78 Argentina HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 79 Argentina HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 80 Middle East & Africa HPV associated disorders market, by country, 2021 - 2033 (USD Million)
  • Table 81 Middle East & Africa HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 82 Middle East & Africa HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 83 Middle East & Africa HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 84 South Africa HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 85 South Africa HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 86 South Africa HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 87 Saudi Arabia HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 88 Saudi Arabia HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 89 Saudi Arabia HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 90 UAE HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 91 UAE HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 92 UAE HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 93 Kuwait HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 94 Kuwait HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 95 Kuwait HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 HPV associated disorders market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and application outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 HPV associated disorders market dynamics
  • Fig. 12 HPV associated disorders market: Porter's five forces analysis
  • Fig. 13 HPV associated disorders market: PESTLE analysis
  • Fig. 14 Type market, 2021 - 2033 (USD Million)
  • Fig. 15 Cervical Intraepithelial Neoplasia (CIN) market, 2021 - 2033 (USD Million)
  • Fig. 16 Cervical Cancer market, 2021 - 2033 (USD Million)
  • Fig. 17 Anal Intraepithelial Neoplasia (AIN) market, 2021 - 2033 (USD Million)
  • Fig. 18 Anal Cancer market, 2021 - 2033 (USD Million)
  • Fig. 19 Genital Warts market, 2021 - 2033 (USD Million)
  • Fig. 20 Others market, 2021 - 2033 (USD Million)
  • Fig. 21 Treatment market, 2021 - 2033 (USD Million)
  • Fig. 22 Vaccines market, 2021 - 2033 (USD Million)
  • Fig. 23 Anti-viral Drugs market, 2021 - 2033 (USD Million)
  • Fig. 24 Others market, 2021 - 2033 (USD Million)
  • Fig. 25 Distribution Channel market, 2021 - 2033 (USD Million)
  • Fig. 26 Hospital Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 27 Retail Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 28 Others market, 2021 - 2033 (USD Million)
  • Fig. 29 HPV associated disorders market revenue, by region
  • Fig. 30 Regional marketplace: Key takeaways
  • Fig. 31 North America HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 32 U.S. country dynamics
  • Fig. 33 U.S. HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 34 Canada country dynamics
  • Fig. 35 Canada HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 36 Mexico country dynamics
  • Fig. 37 Mexico HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 38 Europe HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 39 UK country dynamics
  • Fig. 40 UK HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 41 Germany country dynamics
  • Fig. 42 Germany HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 43 France country dynamics
  • Fig. 44 France HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 45 Italy country dynamics
  • Fig. 46 Italy HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 47 Spain country dynamics
  • Fig. 48 Spain HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 49 Norway country dynamics
  • Fig. 50 Norway HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 51 Sweden country dynamics
  • Fig. 52 Sweden HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 53 Denmark country dynamics
  • Fig. 54 Denmark HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 55 Asia Pacific HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 56 Japan country dynamics
  • Fig. 57 Japan HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 58 China country dynamics
  • Fig. 59 China HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 60 India country dynamics
  • Fig. 61 India HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 62 Australia country dynamics
  • Fig. 63 Australia HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 64 South Korea country dynamics
  • Fig. 65 South Korea HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 66 Thailand country dynamics
  • Fig. 67 Thailand HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 68 Latin America HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 69 Brazil country dynamics
  • Fig. 70 Brazil HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 71 Argentina country dynamics
  • Fig. 72 Argentina HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 73 MEA HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 74 South Africa country dynamics
  • Fig. 75 South Africa HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 76 Saudi Arabia country dynamics
  • Fig. 77 Saudi Arabia HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 78 UAE country dynamics
  • Fig. 79 UAE HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 80 Kuwait country dynamics
  • Fig. 81 Kuwait HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 82 Company categorization
  • Fig. 83 Company market position analysis
  • Fig. 84 Strategic framework